|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
IL146005A0
(en)
|
1999-05-07 |
2002-07-25 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
WO2001080884A1
(en)
|
2000-04-25 |
2001-11-01 |
Idec Pharmaceuticals Corporation |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
|
CN101555283B
(zh)
|
2001-01-17 |
2012-03-21 |
生物权威国际有限公司 |
针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
|
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
|
ME00426B
(me)
|
2003-04-09 |
2011-10-10 |
Genentech Inc |
Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
|
DK1639014T3
(da)
|
2003-06-13 |
2011-01-17 |
Biogen Idec Inc |
Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
EP1883424A2
(en)
|
2005-05-18 |
2008-02-06 |
Biogen Idec Inc. |
Methods for treating fibrotic conditions
|
|
EP2975057A1
(en)
|
2006-07-10 |
2016-01-20 |
Fujita Health University |
Novel anti-cd73 antibody
|
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
|
AU2013216320A1
(en)
*
|
2012-02-01 |
2014-04-03 |
Compugen Ltd. |
C10RF32 antibodies, and uses thereof for treatment of cancer
|
|
US9090697B2
(en)
|
2013-03-15 |
2015-07-28 |
Bayer Healthcare Llc |
Methods for treating bleeding disorders
|
|
WO2014153424A1
(en)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
|
|
US20180030144A1
(en)
|
2014-10-10 |
2018-02-01 |
Innate Pharma |
Cd73 blockade
|
|
WO2016055609A1
(en)
|
2014-10-10 |
2016-04-14 |
Innate Pharma |
Cd73 blockade
|
|
RS62003B2
(sr)
|
2014-11-10 |
2025-01-31 |
Medimmune Ltd |
Vezujući molekuli specifični za cd73 i njihove upotrebe
|
|
EP3789403A1
(en)
*
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
|
JP6805142B2
(ja)
*
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３に対する抗体およびその使用
|
|
EP3259288B1
(en)
|
2015-02-20 |
2026-07-22 |
Innate Pharma |
Cd73 blockade
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
CA3007646A1
(en)
|
2015-12-09 |
2017-06-15 |
Bioatla, Llc |
Humanized anti-cd73 antibodies
|
|
AU2017228470A1
(en)
*
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
EP3481869A4
(en)
*
|
2016-07-11 |
2020-02-26 |
Corvus Pharmaceuticals, Inc. |
ANTI-CD73 ANTIBODIES
|
|
CA3046432A1
(en)
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anti-human cd73 antibody
|
|
CA3045376C
(en)
|
2017-01-24 |
2022-08-30 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
|
WO2018187512A1
(en)
|
2017-04-04 |
2018-10-11 |
Corvus Pharmaceuticals, Inc. |
Methods for treating cd73hi tumors
|
|
WO2018215535A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
|
WO2019170131A1
(zh)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
|
|
CN119431579A
(zh)
*
|
2018-03-09 |
2025-02-14 |
艾吉纳斯公司 |
抗cd73抗体及其使用方法
|
|
AU2019231172B2
(en)
*
|
2018-03-09 |
2023-08-24 |
Phanes Therapeutics, Inc. |
Anti-CD73 antibodies and uses thereof
|
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
WO2019232244A2
(en)
*
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN117304191A
(zh)
|
2018-07-05 |
2023-12-29 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
MX2021005248A
(es)
|
2018-11-05 |
2021-08-11 |
Corvus Pharmaceuticals Inc |
Anticuerpos contra cd73 activadores de células b.
|
|
KR20210093255A
(ko)
|
2018-11-12 |
2021-07-27 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
항-cd73 항체, 이의 항원 결합 단편 및 이의 적용
|
|
CN111499747B
(zh)
|
2019-01-11 |
2022-03-18 |
康诺亚生物医药科技（成都）有限公司 |
一种抗cd73单克隆抗体及其应用
|
|
CN111434688A
(zh)
|
2019-01-11 |
2020-07-21 |
上海开拓者生物医药有限公司 |
Cd73抗体及其制备方法和应用
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
KR20220002959A
(ko)
|
2019-04-23 |
2022-01-07 |
이나뜨 파르마 에스.에이. |
Cd73 차단 항체
|
|
JP7623706B2
(ja)
|
2019-06-06 |
2025-01-29 |
ジャコバイオ ファーマスーティカルズ カンパニー リミテッド |
Ｃｄ７３に特異的な結合分子と結合分子の使用
|
|
CN117946274B
(zh)
|
2019-06-19 |
2026-02-17 |
杭州博之锐生物制药有限公司 |
抗cd73抗体及其应用
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
CN115141277A
(zh)
|
2019-08-21 |
2022-10-04 |
和铂医药(上海)有限责任公司 |
抗cd73抗体及其应用
|
|
PH12022550470A1
(en)
|
2019-08-26 |
2023-02-27 |
Incyte Corp |
Triazolopyrimidines as a2a / a2b inhibitors
|
|
EP4025605A1
(en)
|
2019-09-06 |
2022-07-13 |
Symphogen A/S |
Anti-cd73 antibodies
|
|
CA3159196A1
(en)
|
2019-11-01 |
2021-05-06 |
Corvus Pharmaceuticals, Inc. |
Immunomodulatory anti-cd73 antibodies and uses thereof
|
|
EP4058150A2
(en)
|
2019-11-15 |
2022-09-21 |
Genzyme Corporation |
Biparatopic cd73 antibodies
|
|
EP4076669A4
(en)
|
2019-12-19 |
2024-01-10 |
Board of Regents, The University of Texas System |
METHOD FOR TREATING GLIOBLASTOMA
|
|
EP4084870A1
(en)
|
2020-01-03 |
2022-11-09 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
|
CR20220317A
(es)
|
2020-01-03 |
2022-09-02 |
Incyte Corp |
Anticuerpos anti-cd73 y usos de estos
|
|
BR112022020256A2
(pt)
|
2020-04-09 |
2023-01-03 |
Aprilbio Co Ltd |
anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
|
|
WO2021213466A1
(zh)
|
2020-04-22 |
2021-10-28 |
中山康方生物医药有限公司 |
抗cd73的抗体及其用途
|
|
CN115551888B
(zh)
|
2020-05-12 |
2026-04-28 |
百欧恩泰(珠海)医药研发有限公司 |
抗cd73抗体及其用途
|
|
CN115867582A
(zh)
|
2020-05-29 |
2023-03-28 |
朝途生物疗法株式会社 |
抗cd73抗体及其用途
|
|
CN115734972A
(zh)
|
2020-06-22 |
2023-03-03 |
信达生物制药(苏州)有限公司 |
抗cd73抗体及其用途
|
|
JP2024502005A
(ja)
|
2020-12-29 |
2024-01-17 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
|